Has drug therapy changed the natural history of Parkinson's disease?

Journal of Neurology

Volumn 257, Issue SUPPL. 2, 2010, Pages

  Clarke, C E ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

Levodopa; Mortality; Natural history; Parkinson's disease; Treatment

Indexed keywords

DOPAMINE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PRAMIPEXOLE; RASAGILINE; ANTIPARKINSON AGENT;

CONFERENCE PAPER; DEMENTIA; FALLING; HISTORY; HUMAN; MORTALITY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE;

ANTIPARKINSON AGENTS; HUMANS; PARKINSON DISEASE; SURVIVAL RATE;

EID: 80053375103     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-010-5716-z     Document Type: Conference Paper

References (14)

1. Clarke CE (1993) Mortality from Parkinson's disease in England and Wales 1921-1989. J Neurol Neurosurg Psychiatry 56:690-693
2. Clarke CE (1995) Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord 10(3):250-256
3. Clarke C (2000) Mortality from Parkinson's disease. J Neurol Neurosurg Psychiatry 68(2):254-255
4. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17:427-442
5. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60(3):387-392 (Pubitemid 36314364)
6. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A et al (2004) Levodopa and the progression of Parkinson's disease [see comment]. N Engl J Med 351(24):2498-2508
7. Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P et al (2002) Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of Parkinsonism trial. Ann Neurol 51(5):604-612
8. Parkinson Study Group (2004) A controlled, randomised, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61:561-566
9. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A et al (2009) A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361(13):1268-1278
10. Clarke CE (2008) Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Mov Disord 23(6):784-789
11. Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ et al (2008) Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev (2):CD006564
12. Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE et al (2004) Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 329(7466):593
13. Weintraub D (2008) Dopamine and impulse control disorders in Parkinson's disease. Ann Neurol 64(Suppl 2):S93-S100
14. Schapira AH, Albrecht S, Barone P, Comella CL, McDermott MP, Mizuno Y et al (2010) Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study. Mov Disord 25:1627-1632